Athira Pharma Inc
1 day chart
Athira Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing small molecules to restore neuronal health and stop neurodegeneration. Its pipeline consists of both blood brain barrier (BBB) permeable and peripherally restricted drug candidates for the central nervous system (CNS), peripheral nervous system (PNS), and other indications. Its lead candidate, fosgonimeton (ATH-1017), is a subcutaneously administered, small molecule positive modulator of the hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/MET) system for CNS disorders. It is also advancing potential drug candidates for neuropathic pain, amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases. Its neuropathic pain drug candidate, ATH-1020, completed a Phase I single ascending dose evaluation in healthy volunteers. Its ATH-1105 is a small molecule compound designed to be an orally available, once-daily treatment to enhance the HGF/MET system.
Buy US stocks in Australia starting with ATHA. Open an account and start investing today!
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in ATHA
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.